Overview

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Status:
Terminated
Trial end date:
2017-03-14
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Bispecific
Antineoplastic Agents
Blinatumomab